Rilmenidine modulates intracellular accumulation of ABC transporter substrates in pancreatic ductal adenocarcinoma cells
Open Access
- 1 January 2026
- journal article
- Published by National Library of Serbia in Archives of Biological Sciences
- No. 00,p. 22
Abstract
The antihypertensive drug rilmenidine has been investigated as a candidate for drug repurposing in oncology for its cytotoxic and antimetastatic properties through activation of the tumor suppressor nischarin. We recently observed that the presence of rilmenidine was associated with fluorescent dye accumulation in pancreatic ductal adenocarcinoma (PDAC) cell lines. This study was designed to examine whether rilmenidine has the potential to modulate the accumulation of dyes and chemotherapeutics known to be ABC transporter substrates. We screened a panel of PDAC cell lines for expression of MDR-related ABC transporters (ABCB1, ABCC1, ABCC2, and ABCG2) and selected PANC-1, MIA PaCa-2, and AsPC-1 cell lines as model systems. We found that rilmenidine treatment attenuated the efflux of calcein, Hoechst 33342, and doxorubicin, implying modulation of ABCB1, ABCC1, and ABCC2 pump activity in a manner comparable, but weaker than known inhibitors. In silico examination suggested that rilmenidine could bind to the ligand pockets of these pumps. Finally, rilmenidine potentiated the effects of 5-fluorouracil (5-FU) and paclitaxel in PDAC cells measured in vitro. These findings suggest that rilmenidine can modulate MDR-associated ABC transporter activity and should be considered when evaluating its potential for repurposing in cancer therapy.Keywords
Funding Information
- Ministarstvo Prosvete, Nauke i Tehnološkog Razvoja (451-03-33/2026-03/200043. This research was supported by the Science Fund of the Republic of Serbia, PROMIS 6056979, REPANCAN, and the European Union’s Horizon 2020 research and innovation program under the Marie Skłodowska-Curie 891135)